Stock Analysis, Dividends, Split History

ASX:RMD / RESMED INC financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Pricen/a
Volumen/a
Market Cap ($M)0.00
Enterprise Value ($M)81.29
Book Value ($M)2,058.98
Book Value / Share14.43
Price / Bookn/a
NCAV ($M)60.77
NCAV / Share0.43
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 142,684,034
Common Stock Shares Outstanding 142,679,632
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.14
Return on Assets (ROA)0.09
Return on Equity (ROE)0.16
Balance Sheet (mrq) ($M)
Assets3,063.92
Liabilities1,004.94
Quick Ratio1.56
Current Ratio2.08
Income Statement (mra) ($M)
Sales Revenue Goods Net2,340,196,000.00
Revenues2,340,196,000.00
Operating Income541.83
Net Income315.59
Earnings Per Share Diluted2.19
Earnings Per Share Basic2.21
Cash Flow Statement (mra) ($M)
Cash From Operations505.03
Cash from Investing-101.82
Cash from Financing-101.82
Identifiers and Descriptors
Central Index Key (CIK)943819

Split History

Stock splits are used by RESMED INC to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

ResMed Unveils AirFit F30, Expands AirFit Mask Portfolio

2018-09-18 zacks
ResMed (RMD - Free Report) recently expanded its AirFit mask portfolio with the introduction of its first minimal-contact full face CPAP mask — AirFit F30. The company plans to launch the product in selected geographies in late-2018. (1-0)

UPDATE 1-NZ's Fisher & Paykel cuts FY guidance on ResMed-linked legal costs

2018-09-02 reuters
Sept 3 (Reuters) - New Zealand medical device firm Fisher & Paykel Healthcare Corp cut its fiscal 2019 net profit outlook on Monday on the back of expected legal costs to contest patent allegations made by ResMed Inc.

NZ's Fisher & Paykel Healthcare cuts FY guidance on higher expected legal costs

2018-09-02 reuters
Sept 3 (Reuters) - New Zealand medical device firm Fisher & Paykel Healthcare Corp cut its fiscal 2019 net profit outlook on Monday on the back of expected legal costs to contest patent allegations made by ResMed Inc.

Tap the Sleep Apnea Devices Market Boom With These 3 Stocks

2018-08-27 zacks
Favorable consumer behavior, growing demand for liquid biopsy tests along with deferred implementation of an industry-wide Medical Device tax have created a safe haven for medical device companies. As the U.S. Medical Device industry is likely to reach a worth of $173 billion by 2019, per Emergo, it is currently enjoying the investment world’s attention.

Masimo's SET Pulse Oximetry Detects Sleep Apnea in Children

2018-08-15 zacks
Masimo Corporation (MASI - Free Report) recently announced that its SET Measure-through Motion and Low Perfusion pulse oximetry might be a useful initial screening method to identify children with Down Syndrome (DS) who are at a high risk of obstructive sleep apnea (OSA).

The 9 Best Stocks to Buy for the Next Decade

2018-08-13 investorplace
Last year, InvestorPlace contributor Dan Burrows highlighted the 10 best-performing S&P 500 stocks of the past decade. The most important lesson one finds studying these high-flying stocks is that patience wins out over all other attributes of a successful investor. (64-2)

ResMed Inc. 2018 Q4 - Results - Earnings Call Slides

2018-08-03 seekingalpha
The following slide deck was published by ResMed Inc. in conjunction with their 2018 Q4 earnings call.

ResMed (RMD) Q4 Earnings & Sales Beat on Overall Growth

2018-08-03 zacks
ResMed Inc. (RMD - Free Report) announced fourth-quarter fiscal 2018 adjusted earnings per share (EPS) of 95 cents, up 23.4% from the prior-year quarter. Earnings beat the Zacks Consensus Estimate of 90 cents by 5.6%. (2-0)

ResMed (RMD) Q4 2018 Results - Earnings Call Transcript

2018-08-03 seekingalpha
Welcome to the Q4 Fiscal Year 2018 ResMed Incorporated Earnings Conference Call. My name is Tim and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we'll conduct a question-and-answer session. Please note that this conference is being recorded.

ResMed (RMD) Q4 Earnings and Revenues Top Estimates

2018-08-03 zacks
ResMed (RMD - Free Report) just came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.90 per share. This compares to earnings of $0.77 per share a year ago. These figures are adjusted for non-recurring items.